Experts in China have made new progress in the treatment of early triple negative breast cancer

Xinhua News Agency, Guangzhou, December 12 (Xinhua Xu Hongyi) reporter 11 from Sun Yat-sen University Cancer Prevention and Control Center was informed that the center's breast cancer team in the early treatment of triple-negative breast cancer made new progress, found that the use of "beat chemotherapy" way of chemotherapy drug Carpenthamin maintenance treatment, can significantly improve the early three-negative breast cancer patients 5 years disease-free survival rate. The study was published in jamA, one of the world's leading medical journals.
cancer is the most common malignant tumor in women, of which three-negative breast cancer is the subtype with the highest recurrence rate and mortality rate. Chemotherapy is the main means to reduce the risk of recurrence of early tri-negative breast cancer, but the efficacy has reached a bottleneck, clinically more effective means to improve the cure rate of early triple-negative breast cancer.
Kapethamin is a chemotherapy drug that has been used clinically for many years and has good ability and safety in advanced tumors through a new type of "beat chemotherapy" that is taken oral at low doses and at high frequencies. Inspired by this, Sun Yat-sen University Cancer Prevention and Control Center Yuan Zhongyu, Wang Wei, Wang Shusen and other breast cancer experts led the team to focus on early triple negative breast cancer, Capaithambin "beat chemotherapy" as a maintenance treatment effect to carry out research. The study began in 2010 and was successfully completed this year through the joint efforts of 13 domestic cooperative units.
The results of this study showed that patients continued to use carpental therapy in a low-dose, high-frequency "beat chemotherapy" mode after the end of standard treatment, which reduced the risk of recurrence of early triple-negative breast cancer by more than 1/3 and increased the patient's five-year disease-free survival rate from 73.0% to 82.8%.
Zhongyu, director of internal medicine at Sun Yat-sen University's Oncology Prevention and Control Center, said that the safety of "beat chemotherapy" was good, and 83% of patients were able to successfully complete the entire course of treatment without severe toxic side effects. "In addition, the total cost of maintaining treatment for one year using domestic Capedabin is less than 4000 yuan, after reimbursement of medical insurance and other patients only need to bear about 1000 yuan, with a good cost-effective and universal."